Comparative study of the efficacy and tolerance of intravenously administered azithromycin (1.5 g) given either as a single dose or over a 3 day period in patients with community-acquired pneumonia

Medical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases0 个研究点目标入组 300 人开始时间: 2006年7月26日最近更新: 2013年3月25日

适应症

试验速览

暂无简介。

•Female or male, aged between 18 and 90 years, who achieve the criteria of risk classes II – IV after the scoring system of Bartlett et al. (Clin. Infectious Diseases 2000) (17).
•Written informed consent.
•Chest radiograph showing a new pulmonary infiltrate and two or more of the following clinical data: fever > 38°C, cough, dyspnea (respiratory rate over 20/min), elevated C-reactive protein or elvated (>10 G/L) or leukopenia (< 4 G/L) ,signs of consolidation on respiratory auscultation and a purulent sputum.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Pregnancy or lactation.
•Hemodialysis or hemofiltration.
•Impaired hepatic function with arised liver parameters.
•Allergy or hypersensitivity against study drugs.
•Nosocomial pneumonia
•Already hospitalized patients with pneumonia
•Severe asthma or cystic fibrosis
•Immunosuppression or asplenia
•Previous participation in a study in the last 6 weeks
•Known or suspected current infection that requires treatment with (an) additional anti-bacterial agent(s).
•Concurent medication like ergotamine, theophylline or digitalis.
•Achieving the criteria of risk group V after the scoring systemof Bartlett et.al.

发起方

Medical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases